•			
Please type a plus sign inside this box +	PTO/SB/08A(05/03)	Approved for use thro	ough 05/31/2003, OMB 0651-0031
		Application Number	10/663,109
INFORMATION DISCLOSURE STATEMENT BY-APPLICANT (Use as many sheets as frecessary)		Filing Date	September 15, 2003
		First Named Inventor	Rustum, et al.
		Art Unit	1614
		Examiner Name	Frederick F. Krass
Sheet /1 8	2	Attorney Docket Number	003551.00136

		1 SEP 2 1 7007 W	1		
170			U.S. PATENT DOCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	. 1	US-2004/0197430 A1	10/07/2004	Meyrowitz	
	2	US-4,564,634	01/1986	Revici, Emanual	
	3	US-6,090,414	07/2000	Passwater, et al.	
	4	US-6,197,295	03/2001	Hsia, et al.	
	5	US-2001/0044431	11/2001	Rodriguez, Gustavo C	
	ļ				
	·				

		FOREIGN P.	ATENT DOCUME	NTS		
Examiner	more I l'ite	Name of Patentee or	Pages, Columns, Lines Where Relevant			
Initials* No. 1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	т ⁶	
	6	WO 00/67762	11-16-2000	Anticancer, Inc.		
	7	WO 99/64018	12/16/1999	Biosyn Arzneimittel GMBH		
	ļ					

Examiner	Date	
Signature	Considered	

BFLODOCS 2000765 v1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of

Approved for use time	ough 03/31/2003, Olvid 0031-0031
Application Number	10/663,109
Filing Date	September 15, 2003
First Named Inventor	Rustum, et al.
Group Art Unit	1614
Examiner Name	Frederick F. Krass
Attorney Docket Number	003551.00136

Examiner Initials* Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	8	KONOREV, et. al., Cell-Permeable Superoxide Dismutase and Glutathione Peroxidase Mimetics Afford Superior Protection Against Doxorubucin-Induced Cardiotoxicity: The Role of Reactive Oxygen and Nitrogen Intermediates, Archives Biochem. Biophysics, 1999, 368 (2), pp. 421-428, abstract.	
	9	KORAC, et al., Doxorubicin, Toxicity to the Skin: Possibility of Protection With Antioxidants Enriched Yeast, J. Dermat. Sci., 2001, 25 (1) pp. 45-52, abstract.	
	10	CHEN, et al., Protective Effects of Selenium Supplementation in Minimizing 5-Glorouracil Induced Lipid Peroxidative Damage of the Small Intestine, J. Trace Elements in Experimental Med., 1997, 10 (3), p. 163-171.	
	11	VADGAMA J. et. al., Effect of Selenium in Combination With Adriamycin or Taxol on Several Different Cancer Cells, Anticancer Research 20:1391-1414, 2000.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BFLODOCS 2000765 v1

Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached. Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.